Research / PRHI / Fundamental state Inspectable configuration
State dimensions Filing 0001193125-25-179796 Insurance
Cash 71th Own-history percentile · N=14
Evidence method Level · gp.fundamentals.cash
$22.0M · CORE · VALID
Debt 14th Own-history percentile · N=14
Evidence method Level · gp.fundamentals.gross_debt
$12.1M · OPTIONAL · VALID
Premium growth 0th Own-history percentile · N=10
Evidence method Yoy · gp.insurance.premiums
-42.61% · CORE · VALID
Revenue growth 10th Own-history percentile · N=10
Evidence method Yoy · gp.fundamentals.revenue
-39.91% · CORE · VALID
As-filed lineage Fundamental state history Each observation is tied to the filing and facts available at that report date. Amendments remain separate.
History 15 states Self-history eligible
Dec 31, 2022 0/4 normalized Level 3 Mar 31, 2023 0/4 normalized Level 3 Jun 30, 2023 0/4 normalized Level 3 Sep 30, 2023 0/4 normalized Level 3 Dec 31, 2023 2/4 normalized Level 3 Mar 31, 2024 2/5 normalized Level 3 Jun 30, 2024 2/4 normalized Level 3 Sep 30, 2024 2/4 normalized Level 3 Dec 31, 2024 4/4 normalized Level 3 Mar 31, 2025 4/5 normalized Level 3 Jun 30, 2025 4/4 normalized Level 3 Sep 30, 2025 4/5 normalized Level 3 Dec 31, 2025 4/5 normalized Level 3 Mar 31, 2026 4/5 normalized Level 3 Jun 30, 2026 4/5 normalized Level 4 Period transition
What moved in the state? Cash Increased
Previous $10.3M
Current $22.0M
Delta $11.7M Debt Increased
Previous $12.0M
Current $12.1M
Delta $64,000 Premium Growth Decreased
Previous -38.92%
Current -42.61%
Delta -3.70% Revenue Growth Decreased
Previous -31.21%
Current -39.91%
Delta -8.69% Self-history only Previous similar states Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.
Not enough compatible prior states for a transparent self-history match.
Research Graph
Related governed research Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.